Loading patent…
AssigneeThe Trustees of the University of Pennsylvania
InventorsJames L. Riley, Carl H. June, Robert H. Vonderheide, Nicole Aqui, Megan M. Davis
Estimating the term…
The invention relates to novel artificial antigen presenting cells (aAPCs). The aAPC comprises at least one stimulatory ligand and at least one co-stimulatory ligand where the ligands each specifically bind with a cognate molecule on a T cell of interest, thereby mediating expansion of the T cell. The aAPC of the invention can further comprise additional molecules useful for expanding a T cell of interest. The aAPC of the invention can be used as an “off the shelf’ APC that can be readily designed to expand a T cell of interest. Also, the aAPC of the invention can be used identify the stimulatory, co-stimulatory, and any other factors that mediate growth and expansion of a T cell of interest. Thus, the present invention provides powerful tools for development of novel therapeutics where activation and expansion of a T cell can provide a benefit.
(canceled)
An isolated artificial antigen presenting cell (aAPC) comprising a K562 cell transduced with a viral vector, wherein said viral vector comprises a nucleic acid encoding at least one co-stimulatory ligand that specifically binds with at least one co-stimulatory molecule selected from the group consisting of CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, LFA-1, CD2, CD7, LIGHT, NKG2C, B7-H3, BTLA, Toll ligand receptor and a ligand that specifically binds with CD83, and said viral vector further comprises a nucleic acid encoding a CD64 molecule, and wherein said aAPC expresses said co-stimulatory ligand and said CD64 molecule, and further wherein said CD64 is loaded with an anti-CD3 antibody, and further wherein said aAPC can stimulate and expand a T cell contacted with said aAPC.
Dependencies are inferred from the claim text.